Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

GHLF letter supporting MA H.1894 & H.3465

Dec 15// Letters and Testimony

Chairwoman Hogan and Chairman Lewis,

The Global Healthy Living Foundation (GHLF) is a 501(c)(3) patient group that works to improve the quality of life for people with chronic disease, often focusing on those least able to advocate for themselves.

READ MORE

GHLF 50 State Network support P C1952

Sep 08// Letters and Testimony

P C1952 takes positive steps toward updating Puerto Rican law to cover biologics and interchangeable biosimilars in a way that protects patients. Unlike traditional chemical drugs, biologics are unique, complex structures made from living cells that are not easily replicated. A small change or difference in the biosimilar or biologic manufacturing process has the potential to adversely impact the patient.

READ MORE

GHLF CMS Biosimilar J-Code Proposal

Sep 04// In Action

The Global Healthy Living Foundation (GHLF) is a 501 (c)(3) patient group that works to
improve the quality of life for people with chronic disease, often focusing on those least able to advocate for themselves.

READ MORE

The FDA Introduces Naming Conventions for Biosimilars

Sep 02// GHLF in the news

Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.

READ MORE

Maligned FDA Deserves Standing Ovation

Sep 02// GHLF in the news

Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.

READ MORE

Victory in the USA

Aug 28// Victories

Thank you Advocates! FDA Issues Draft Guidance for Biosimilar Naming: A Proposed Rule that Designates Official Names and Proper Names for Certain Biological Products Your efforts are making a difference. GHLF is pleased to share that the Food and Drug Administration (FDA) released a draft guidance requiring biological products licensed under the Public Health Service […]

READ MORE

Victory in Illinois

Aug 03// Victories

GHLF applauds our CreakyJoints community for taking action!

READ MORE

Texas Pharmaceutical & Therapeutics Committee – July Meeting outcome

Jul 29// Letters and Testimony

On July 24th, the Texas Pharmaceutical and Therapeutics (P&T) Committee, a part of the Texas Health and Human Services Commission, convened to review a number of different medications and medication classes for entry onto their Preferred Drug List (PDL) of the Texas Medicaid Formulary. A medication to alleviate symptoms of opioid-induced constipation (OIC) was one […]

READ MORE

7/9/2015 – Teleconference with Assemblywoman Jaffee

Jul 29// Events

Assemblywoman Jaffee provided our listeners with some important advice about the power of the patient perspective. Listen to what she had to say:

READ MORE

5 reasons biosimilars must have distinguishable names

Jul 27// GHLF in the news

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.

READ MORE